الفهرس 
AcknowledgmentOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Cisplatin is one of themost effective anticancer agents currently available for the treatment of testicular, ovarian, and bladder carcinoma, but its clinical usefulness has frequently been limited by undesirable side effects such as nephrotoxicity, gastrointestinal toxicity, ototoxicity, and neurotoxicity. The aim of the present study is to avoid the toxic side effects of Cisplatin using some protectors. One hundred and sixty (160) pregnant females were used in the teratogenicity investigation. Cisplatin administrated intraperitoneally (at 5 mg/Kg) as a single dose on 12th day of gestation. Oral administration of N-acetyl-cysteine (NAC) and/ or Sodium selenate throughout gestation in concomitant injection of Cisplatin showed reduction in the elevated morphological, visceral and skeletal abnormalities as well as the reduction of the morphological and histopathological changes in placenta compared to Cisplatin - treated rats. This reduction was significant in Sodium selenate + Cisplatin and NAC+ Sodium selenate + Cisplatin- groups, while it was statistically insignificant in NAC + Cisplatin group compared to Cisplatin- treated group.